<DOC>
	<DOCNO>NCT01121237</DOCNO>
	<brief_summary>MONITOR-CKD5 observational , pharmaco-epidemiological study evaluate multi-level factor outcomes associate treatment renal anaemia biosimilar epoetin alfa Stage 5 CKD patient require haemodialysis .</brief_summary>
	<brief_title>MONITOR-CKD5 - Multi-level Evaluation Anaemia Treatment , Outcomes , Determinants Chronic Kidney Disease Stage 5</brief_title>
	<detailed_description>See follow publication : Gesualdo , L. , London , G. , Turner , M. , Lee , C. , MacDonald , K. , Covic , A. , Zaoui , P. , Combe , C. , Dellana , F. , Muenzberg , M. , &amp; Abraham , I . ( press ) . A pharmacoepidemiological study multi-level determinant , predictor , clinical outcome biosimilar epoetin alfa renal anemia hemodialysis patient : background methodology MONITOR-CKD5 study . Internal Emergency Medicine . ( DOI 10.1007/511739-011-0622-7 )</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female adult ( age &gt; 18 year ) . On chronic haemodialysis due endstage renal disease ( CKD5 ) original graft kidney duration . Diagnosed renal anaemia ; i.e. , anaemia due impaired production endogenous erythropoietin secondary kidney failure . Treated commercially available intravenous EPOETIN ALFA HEXAL® per physician 's best clinical judgment consideration available guidance evidence . Female patient must either postmenopausal one year surgically sterile use effective contraceptive method barrier method spermicide intrauterine device . Oral contraceptive use allow . Informed write consent participate study patient legal guardian . Known sensitivity EPOETIN ALFA HEXAL® ESA . Solid hematological neoplasia treat chemotherapy . Treatment myelosuppressant medication . Blood transfusion dependency . History pure red cell aplasia . Bleeding episode 30 day prior enrollment . Orthopaedic surgery 30 day prior enrollment . Patients several medical condition ( ) view investigator prohibit participation study . Patients willfully negligent nonadherence haemodialysis , medication , nutrition , and/or recommend treatment regimen . Use investigational agent 30 day prior enrollment . Women childbearing potential use contraception method ( ) describe . Women breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>renal anaemia</keyword>
	<keyword>epoetin alfa</keyword>
</DOC>